ABSTRACT A specific carboxypeptidase that converts enkephalin precursors into enkephalin in adrenal chromaffin granules has been purified and characterized. In the adrenal this enzyme, designated enkephalin convertase, is uniquely localized to the chromaffin granules, which contain enkephalin and precursor peptides. Enkephalin convertase is markedly stimulated by CoC12 and inhibited by EDTA or 1,10-phenanthroline, unlike the lysosomal carboxypeptidase. The purified enzyme has a high affinity for the hexapeptides Brain enkephalin convertase shows 10-fold regional variations, unlike other carboxypeptidases, which are uniformly distributed. Enkephalin convertase appears to be associated selectively and physiologically with biosynthesis of the enkephalins.
Most biologically active peptides are synthesized from large peptide precursors by sequential actions of a trypsin-like enzyme followed by a carboxypeptidase B-like activity that removes basic amino acids from the carboxyl terminus ofthe trypsin fragments (1) . Large enkephalin precursor peptides have been identified in which the enkephalin sequence is surrounded by dibasic amino acid pairs (2, 3) . Moreover, hexapeptides comprising the enkephalin sequence with an arginine or lysine at the carboxyl terminus have been isolated from brain and adrenal (4) . It is unclear whether the biosynthesis of biologically active peptides involves carboxypeptidases uniquely concerned with the formation of a single peptide or whether general carboxypeptidases serve this function.
In the adrenal, enkephalins are localized to chromaffin granules, from which they are released together with catecholamines after cholinergic stimulation (5) . If enkephalin is synthesized by a unique carboxypeptidase, such an enzyme might be selectively localized to chromaffin granules and might exhibit selective affinity for enkephalin-containing hexapeptides.
Conventional assays for carboxypeptidase are often nonspecific, insensitive, or, if they utilize the biologically active peptide precursor, time consuming. We have designed a novel carboxypeptidase assay using a fluorescent enkephalin analog. The assay is simple, sensitive, and specific. We now describe a unique cobalt-stimulated carboxypeptidase that, in the adrenal, is concentrated in chromaffin granules and that has selective affinity for enkephalin-containing peptides. This enzyme, designated enkephalin convertase, appears to be selectively associated with physiological synthesis of the enkephalins.
MATERIALS AND METHODS Synthesis of Dansylphenylalanylleucine. L-Phenylalanyl-Lleucine (100 mg) was dissolved in 20 ml of pyridine. Dansyl chloride (200 mg) was added and the mixture was stirred for 5 hr, acidified with dilute HC1 (pH 1 to 2), and extracted with 1 liter ofCHCl3. The chloroform was dried (MgSO4) and removed at reduced pressure, yielding a bright yellow oily solid. The product was purified by TLC on 1-mm silica GF (Analtech) using chloroform/methanol (4:1). Dansyl-Phe-Leu (Rr 0.5) was eluted with hot methanol, yielding 95 mg of product.
Synthesis of Dansylphenylalanylleucylarginine. Dansylphenylalanylleucine (85 mg) was dissolved in 6 ml ofacetonitrile and the solution was cooled in ice bath. N-Hydroxysuccinimide (30 mg) and dicyclohexylcarbodiimide (52 mg) were added and the mixture was stirred 1 hr in an ice bath and then overnight at room temperature. The mixture was cooled and filtered, and the solvent was removed at reduced pressure, yielding 115 mg of yellow oil. The oil was dissolved in 7.5 ml of dimethylformamide, 300 mg of L-arginine-HCl in 2.5 ml of H20 was added, and the mixture was stirred overnight. Twenty milliliters of0.1 M HC1 was added and the aqueous phase was washed with six 50-ml portions of CH2Cl2. The product was partially purified by cation exchange chromatography (Dowex AG-50W-X2). Then, the crude aqueous phase was loaded directly onto 2 g of the resin (prepared as directed). The column was washed with 0.1 M acetic acid and then with H20. Dansyl-Phe-Leu-Arg was removed by elution with 1 M NH40H, which was removed by lyophilization. TLC using ethyl acetate/isopropanoVwater/ acetic acid (40:40:19:1) showed the product to be 90% pure (ninhydrin staining shows free arginine). Dansyl-Phe-Leu-Arg was dissolved in a small volume ofCHCl3/MeOH (4:1) and applied to a 20-ml silica column. The column was washed with 20 ml ofCHCl3/MeOH (4:1) and then the product was eluted with 20 ml of CHCl3/MeOH (1:1). Fractions containing product were pooled and the solvent was removed at reduced pressure, yielding 40 mg of dansyl-Phe-Leu-Arg (>99% pure). Acid hydrolysis (6 M HCl) at reduced pressure at 110°C (overnight) followed by amino acid determination (TLC) confirmed the identity of the product.
Carboxypeptidase Assay. Enzyme, substrate (40 ,uM dansylPhe-Leu-Arg), and buffer (50 mM NaOAc, pH 5.6) are incubated at 37°C for 10 min in 10 x 13 mm fluorometer test tubes (VWR Scientific). For a typical reaction volume of 0.5 ml, the reaction is quenched with 50 ,ul of 1 M HCl. Chloroform (1.5 ml) is then added directly to the assay tubes, which are spun on a Vortex (10 sec) and centrifuged (1 min at 2,000 x g). The * To whom reprint requests should be addressed.
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Purification of Enkephalin Convertase. The 1.6 M sucrose pellets from 10 adrenals were suspended in 5 mM NaOAc (pH 6.0) and the suspension was frozen slowly, thawed, and centrifuged at 100,000 x g for 60 min. The supernatant was decanted, dialyzed against 10 mM NaOAc (pH 6.0), and applied to a 3-ml agarose-Leu-Arg affinity column synthesized from Affi-Gel 10 (Bio-Rad) and L-leucyl-L-arginine (Bachem Fine Chemicals, Torrance, CA) by standard procedures. The column was washed with 10 ml of 0.1 M NaCl/10 mM NaOAc, pH 6 .0. Enkephalin convertase was eluted with 6 ml of 0.1 M L-arginine.HCV10 mM NaOAc, pH 6 .0. Most of the carboxypeptidase activity (>85%) was contained in 2 ml of the eluate and it was loaded directly onto an 80-ml gel filtration column (Sephadex G-200).
The column buffer was 100 mM NaCV10 mM NaOAc, pH 6.0/ 1 mM 2-mercaptoethanol. Fractions (0.5 ml) were collected in tubes containing 0.5 mg of bovine serum albumin (Sigma; fraction V) unless the fraction was to be used for protein determination or gel electrophoresis. Carboxypeptidase activity in both fractions is maximally active at pH 5.5-6.0, corresponding to the intragranular pH of both chromaffin granules and lysosomes (13, 14) .
RESULTS

Subcellular Localization of Enkephalin Convertase in
The differential localization ofcobalt-stimulated and unstimulated carboxypeptidase in sucrose gradients suggests that the cobalt-stimulated enzyme is contained in chromaffin granules while the non-cobalt-stimulated enzyme is localized to lyso- somes and that these activities represent distinct enzymes. This conclusion is supported by the differential effect of inhibitors on carboxypeptidase activity in gradient fractions ofthe adrenal (Fig. 2) . 1, 10-Phenanthroline and cadmium selectively inhibit carboxypeptidase activity in the chromaffin granule portion of the gradient but have much less effect on the lysosomal zone of the gradient. The cobalt-stimulated chromaffin granule carboxypeptidase is designated enkephalin convertase.
Purification of Enkephalin Convertase. We have extensively purified enkephalin convertase from soluble fractions of bovine adrenal chromaffin granules. Approximately 60% of the chromaffin granule carboxypeptidase activity is soluble (100,000 X g for 60 min). The membrane-bound activity is similar to the soluble enzyme with respect to activation and inhibition by divalent ions and enzyme inhibitors (data not shown).
Enkephalin convertase activity binds to an affinity column consisting of L-leucyl-L-arginine linked to agarose. This substrate is both positively and negatively charged at pH 6, so a large amount of protein also adsorbs to the affinity column. Lysosomal carboxypeptidase was purified from sucrose gradient fractions 19-27 by passing the soluble fraction (50,000 x g, 60 min) through the agarose-Leu-Arg affinity column. Approximately 80% of the carboxypeptidase activity was not retained and was used as the lysosomal carboxypeptidase fraction. Ions and inhibitors were incubated 2 hr at 0°C with enzyme, and then substrate (dansyl-Phe-LeuArg) was added to a final concentration of 40 ,iM. The peptide inhibitors were not incubated with enzyme before addition of substrate and were assayed in the presence of 1 mM CoCl2. The following had no effect on enkephalin convertase: 1 mM SrCl2, 1 mM MgCl2, 1 mM BaCl2, 1 mM CaCl2, 1 mM MnCl2, 1 mM iodoacetamide, leupeptin at 10 /g/ml, bacitracin at 100 ,g/ml, soybean trypsin inhibitor at 10 ,ug/ ml, pepstatin A at 10 ,ug/ml, 0.1 mM tosylphenyl chloromethyl ketone, 0.1 mM tosyllysyl chloromethyl ketone, 1 mM succinic acid, 1 mM captopril, chymostatin at 10 ,g/ml, and 1 mM phenylmethylsulfonyl fluoride.
Proc. Natl. Acad. Sci. USA 79 (1982) boxypeptidase. Among the divalent cations, 0. 1 mM cadmium differentiates the two enzymes, markedly inhibiting enkephalin convertase while having a minimal effect on lysosomal carboxypeptidase, whereas copper (0. 1 mM) inhibits both enzymes and strontium, magnesium, barium, and calcium inhibit neither.
In contrast to the inhibitory effects of some divalent cations, cobalt stimulates enkephalin convertase activity 11-fold while having no influence on lysosomal carboxypeptidase. The cobalt stimulation of enkephalin convertase is blocked by zinc which, however, does not affect enkephalin convertase activity in the absence ofcobalt. Nickel can partially stimulate enkephalin convertase but also partially blocks cobalt stimulation.
Enkephalin convertase seems to be less dependent on sulfhydryl groups than lysosomal carboxypeptidase; concentrations of p-chloromercurophenylsulfonate and mercuric chloride that inhibit 90% of lysosomal carboxypeptidase activity produce only 20% inhibition of enkephalin convertase activity.
The selectivity of enkephalin convertase for enkephalin precursors is apparent in the effect ofthe enkephalin hexapeptides, which are more potent in inhibiting enkephalin convertase than lysosomal carboxypeptidase. Interestingly, arginyl[Met]enkephalin and -[Leu]enkephalin hexapeptides are more potent inhibitors ofenkephalin convertase than the corresponding lysyl hexapeptides. By contrast, the arginyl and lysyl hexapeptides inhibit lysosomal carboxypeptidase to a similar extent.
Enkephalin convertase has considerable specificity for peptides having carboxyl-terminal basic amino acids (Table 2) . A large number of di-and tripeptides lacking carboxyl-terminal basic amino acids fail to influence enkephalin convertase activ- Table 2 . Peptide inhibitors of enkephalin convertase Peptide Benzyloxycarbonyl-Gly-Arg Hippuryl-Arg Gly-Gly-Arg Gly-Arg Benzyloxycarbonyl-Ala-Arg Ala-Arg lle-Arg Leu-Arg Phe-Arg Tyr-Arg Arg-Arg Lys-Arg
Ki , AM   180  180  1,170  53  196  94  64  61  133  125  266  297  174  83  195  51  205 The following peptides and amino acids did not significantly (> 15%) inhibit enkephalin convertase at 1 mM (all L-form unless specified): Gly-Gly, Gly-Gly-Glu, Gly-Gly-Trp, Gly-Leu-Gly, Gly-Gly-Pro, GlyGly-Tyr, Gly-Gly-Leu, benzyl-Gly-His-Leu, Gly-Tyr-Gly, Try-Gly-Gly, Nle-Ala, Phe-Met, Phe-Ile, Gly-Thr, Gly-Nva, Gly-Asn, Gly-Gly-Nle, Arg-Glu, (Table 3) . By contrast, apparent enkephalin convertase activity of soluble extracts shows considerable regional variations. Enzyme activity is highest in the thalamus-hypothalamus, corpus striatum, hippocampus, and midbrain, while activity in the cerebellum and brain stem is <1/10th these levels. Cerebral cortical levels of enzyme activity are intermediate.
DISCUSSION
The major finding of the present study is that a cobalt-stimulated carboxypeptidase designated enkephalin convertase appears to be selectively associated with biosynthesis of the enkephalins. Evidence for this is as follows. (i Hippocampus 3.0 5.1 Rat brains were dissected and homogenized (Polytron-Brinkman) in 100 vol of 10 mM NaOAc (pH 6.0). Homogenates were centrifuged at 50,000 x g for 60 min and supernatants were decanted and assayed. Cobalt-stimulated carboxypeptidase activity was determined by subtracting the activity in the presence of 1 mM CoCl2 from the activity in the absence of cobalt. Protein was determined by the Bradford method (8).
Neurobiology: Fricker and Snyder 3890 Neurobiology: Fricker and Snyder potently inhibit the enzyme activity of Hook et al. and lysosomal carboxypeptidase but are much weaker at inhibiting enkephalin convertase. Though Hook et al used an adrenal chromaffin granule preparation for their enzymatic studies, this preparation contains a substantial amount of lysosomes (6, 12, 16, 17) .
Extensive characterization of enkephalin convertase was made feasible by a simple, sensitive, and specific assay using a dansylated enkephalin analog as substrate. Conventional assays monitoring the conversion of enkephalin-Arg6 to enkephalin by HPLC require about 30 min per sample. In contrast, with the dansylated substrate, we can assay 100-200 samples in an hour. Moreover, the fluorescent assay is 100 times more sensitive, readily detecting the formation of 10 pmol ofproduct. While the use of radiolabeled enkephalin hexapeptide substrates provides sensitivity, the assays are substantially more time consuming than the fluorescence procedure.
The data presented here suggest that enkephalin convertase is a specific carboxypeptidase that is physiologically involved in the biosynthesis of the enkephalins. Our partial characterization of the enzyme from brain indicates that the same enzymes are involved in the formation of brain and adrenal enkephalins. The selective association of this enzyme with enkephalin synthesis does not rule out the possibility that it may serve other functions. Thus, DOPA decarboxylase converts dihydroxyphenylalanine into dopamine as well as forming serotonin from 5-hydroxytryptophan. Nonetheless, the existence of a specific enzyme selectively associated with a step of enkephalin biosynthesis suggests that similar selective enzymes might be involved in the biosynthesis of other biologically active peptides.
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